

October 16, 2026

Company name	Japan Medical Dynamic Marketing, INC.
Name of representative	Toshiyuki Hironaka President and Representative Director (Securities code: 7600 ; Tokyo Stock Exchange Prime)
Inquiries	Shinji Munechika General Manager, Investor Relations Office Telephone: +81-3-3341-6705

Notice Regarding Workforce Reduction and Other Rationalization Measures at U.S. Consolidated Subsidiary

The Company hereby announces that, on October 15, 2026, (U.S. time) it resolved to implement workforce reductions and other rationalization measures at Ortho Development Corporation (“ODEV”), the Company’s consolidated subsidiary in the United States, as described below.

1. Reason for Workforce Reduction and Other Rationalization Measure

In response to changes in the business environment and in order to restore business performance and strengthen its earnings base, the Group is promoting structural reforms to its earnings model in both its Japan and U.S. operations. At ODEV, improving profitability has become an important management issue due to factors such as a decline in net sales.

Accordingly, the Company has decided to review ODEV’s organizational structure so that it is aligned with the scale of its business, while also promoting operational efficiency and reducing fixed costs. As part of these efforts, workforce reductions will be implemented at ODEV.

This matter does not involve a withdrawal from ODEV’s business operations. The measures will be implemented on the premise that functions necessary for business continuity, including product supply, quality assurance, and regulatory affairs, will be maintained.

2. Details of Workforce Reduction and Other Rationalization Measures

(1) Affected Departments	Certain departments of ODEV
(2) Number of Employees Affected	Approximately 51 employees (expected)
(3) Timing of Implementation	To be implemented sequentially from October 15, 2026 (U.S. time)
(4) Separation Program	ODEV’s prescribed separation program will be applied to affected employees.

3. Impact on Financial Results

In connection with this matter, the Company expects to record retirement-related expenses and other associated costs in the fiscal year ending March 31, 2027. The total amount of such retirement-related expenses, the expected reduction in personnel expenses and other costs for the fiscal year ending March 31, 2027 resulting from this matter, the impact of these factors on the Company’s consolidated financial results for the same fiscal year, and the expected reduction in personnel expenses and other costs for the fiscal year ending March 31, 2028 and thereafter are currently under review. If any revision to the Company’s financial forecasts or any other matter requiring disclosure arises in the future, the Company will promptly announce it.

4. Overview of ODEV

Item	Description
(1) Name	Ortho Development Corporation
(2) Head Office Location	Draper, Utah, United States
(3) Title and Name of Representative	CEO, Hiroyuki Minamiya
(4) Business Description	Development, manufacture, and sale of medical devices
(5) Capital and the Company's Equity Stake	US\$23,278 thousand; 99.4% (as of March 31, 2026)

Note: This document has been translated from a part of the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.